Literature DB >> 5343152

Carbenoxolone in the treatment of duodenal ulcer.

O Craig, T Hunt, J J Kimerling, D V Parke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5343152

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


× No keyword cloud information.
  15 in total

Review 1.  Medical management of peptic ulcer with reference to anti-ulcer agents in other gastro-intestinal diseases.

Authors:  D W Piper; T R Heap
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 2.  Carbenoxolone sodium.

Authors:  W Sircus
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

3.  A controlled trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer.

Authors:  R D Montgomery; I H Lawrence; D J Manton; K Mendl; P Rowe
Journal:  Gut       Date:  1968-12       Impact factor: 23.059

Review 4.  Carbenoxolone sodium.

Authors:  M J Langman
Journal:  Gut       Date:  1968-02       Impact factor: 23.059

5.  Duogastrone-induced hypokalaemic nephropathy and myopathy with myoglobinuria.

Authors:  A B Mitchell
Journal:  Postgrad Med J       Date:  1971-12       Impact factor: 2.401

6.  The medical treatment of gastric and duodenal ulcer.

Authors:  M J Langman
Journal:  Postgrad Med J       Date:  1968-08       Impact factor: 2.401

7.  Muscle paresis and hypokalemia after treatment with duogastrone.

Authors:  J Forshaw
Journal:  Br Med J       Date:  1969-06-14

8.  Peptic ulcer: surgical treatment.

Authors:  J L Dawson
Journal:  Br Med J       Date:  1969-10-11

9.  Carbenoxolone sodium capsules in the treatment of duodenal ulcer. An endoscopic controlled trial.

Authors: 
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

Review 10.  Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.